MacroGenics Inc (MGNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MacroGenics Inc (MGNX) has a cash flow conversion efficiency ratio of 0.774x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($43.02 Million) by net assets ($55.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MGNX company net worth for the company's overall valuation and market capitalisation.
MacroGenics Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how MacroGenics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MacroGenics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MacroGenics Inc ranked by their cash flow conversion efficiency. Explore MGNX cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ta Chia Yung Ho Machine Industry Co Ltd
TWO:2221
|
0.040x |
|
PennantPark Investment Corporation
NYSE:PNNT
|
0.300x |
|
PT Estee Gold Feet Tbk
JK:EURO
|
-0.067x |
|
CF Bankshares Inc
NASDAQ:CFBK
|
0.026x |
|
ALTEO ENERG.NYIL M.UF125
F:54O
|
N/A |
|
S-Oil Corp Pref
KO:010955
|
0.103x |
|
Arwana Citramulia Tbk
JK:ARNA
|
0.090x |
|
GOLFZON NEWDIN HOLDINGS Co. Ltd
KQ:121440
|
0.007x |
Annual Cash Flow Conversion Efficiency for MacroGenics Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of MacroGenics Inc from 2011 to 2025. View MacroGenics Inc (MGNX) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $55.59 Million | $-81.04 Million | -1.458x | -147.45% |
| 2024-12-31 | $116.06 Million | $-68.37 Million | -0.589x | -14.97% |
| 2023-12-31 | $152.61 Million | $-78.20 Million | -0.512x | +16.31% |
| 2022-12-31 | $142.01 Million | $-86.96 Million | -0.612x | -2.01% |
| 2021-12-31 | $239.62 Million | $-143.83 Million | -0.600x | -58.72% |
| 2020-12-31 | $295.88 Million | $-111.90 Million | -0.378x | +35.04% |
| 2019-12-31 | $230.63 Million | $-134.27 Million | -0.582x | +7.72% |
| 2018-12-31 | $242.88 Million | $-153.23 Million | -0.631x | -1410.61% |
| 2017-12-31 | $299.24 Million | $14.40 Million | 0.048x | +129.62% |
| 2016-12-31 | $268.75 Million | $-43.68 Million | -0.163x | -272.78% |
| 2015-12-31 | $313.34 Million | $-13.66 Million | -0.044x | +83.86% |
| 2014-12-31 | $121.29 Million | $-32.76 Million | -0.270x | -50.40% |
| 2013-12-31 | $78.91 Million | $-14.17 Million | -0.180x | -122.48% |
| 2012-12-31 | $-8.24 Million | $-6.58 Million | 0.799x | +306.75% |
| 2011-12-31 | $-17.48 Million | $6.76 Million | -0.386x | -- |
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical tri… Read more